Brokerages Set Voyager Therapeutics Inc (VYGR) PT at $26.56

Shares of Voyager Therapeutics Inc (NASDAQ:VYGR) have been assigned a consensus rating of “Buy” from the eleven analysts that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eight have given a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $26.56.

A number of equities research analysts have recently commented on the company. Wedbush reaffirmed an “outperform” rating and issued a $28.00 price objective (up previously from $18.00) on shares of Voyager Therapeutics in a research report on Thursday, November 8th. BTIG Research reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Voyager Therapeutics in a research report on Monday, September 10th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $27.00 price objective on shares of Voyager Therapeutics in a research report on Monday, September 10th. Zacks Investment Research raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 11th. Finally, Robert W. Baird lowered their price objective on Voyager Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a research report on Thursday, November 8th.

Shares of NASDAQ:VYGR opened at $11.40 on Friday. The firm has a market capitalization of $371.15 million, a PE ratio of -4.32 and a beta of 3.09. Voyager Therapeutics has a 52 week low of $10.90 and a 52 week high of $31.91.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Wednesday, November 7th. The company reported ($0.63) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.78) by $0.15. The business had revenue of $2.09 million during the quarter, compared to the consensus estimate of $3.02 million. Voyager Therapeutics had a negative return on equity of 81.63% and a negative net margin of 648.40%. As a group, analysts expect that Voyager Therapeutics will post -2.74 EPS for the current year.

In other news, Director James A. Geraghty bought 3,000 shares of Voyager Therapeutics stock in a transaction that occurred on Monday, September 10th. The shares were purchased at an average price of $19.39 per share, for a total transaction of $58,170.00. Following the completion of the acquisition, the director now owns 76,588 shares of the company’s stock, valued at $1,485,041.32. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Glenn Pierce bought 5,000 shares of Voyager Therapeutics stock in a transaction that occurred on Wednesday, September 12th. The stock was purchased at an average price of $18.44 per share, for a total transaction of $92,200.00. The disclosure for this purchase can be found here. 33.60% of the stock is currently owned by company insiders.

A number of institutional investors have recently modified their holdings of VYGR. Metropolitan Life Insurance Co. NY lifted its stake in shares of Voyager Therapeutics by 53.6% during the second quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock worth $177,000 after purchasing an additional 3,157 shares in the last quarter. MetLife Investment Advisors LLC lifted its stake in shares of Voyager Therapeutics by 38.6% during the second quarter. MetLife Investment Advisors LLC now owns 10,649 shares of the company’s stock worth $208,000 after purchasing an additional 2,964 shares in the last quarter. Thompson Davis & CO. Inc. lifted its stake in shares of Voyager Therapeutics by 187.9% during the second quarter. Thompson Davis & CO. Inc. now owns 11,951 shares of the company’s stock worth $234,000 after purchasing an additional 7,800 shares in the last quarter. Man Group plc acquired a new position in shares of Voyager Therapeutics during the third quarter worth about $245,000. Finally, Commonwealth Equity Services LLC lifted its stake in shares of Voyager Therapeutics by 27.4% during the second quarter. Commonwealth Equity Services LLC now owns 16,272 shares of the company’s stock worth $318,000 after purchasing an additional 3,500 shares in the last quarter. Hedge funds and other institutional investors own 88.57% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Featured Article: Why investors pay attention to retained earnings

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit